ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
"The studies performed will allow us to focus our resources on thepreclinical and clinical development of the most potent lead pyrimidinedioneand to gain insight into the molecular features of the compounds which yieldthe high potency and characteristic dual mechanism of antiviral action ofthese unique compounds," explained Dr. Buckheit. Other coauthors on this paperinclude ImQuest virologists Tracy Hartman, Karen Watson and Lu Yang and Samjinchemists Ho-Seok Kwon, Sun-Hwan Lee, Jae-Woong Lee, Dong-Wook Kang, Sun-GanChung and Eui-Hwan Cho.
ImQuest expects to submit an IND to initiate Phase 1 human clinical trialswith IQP-0410, a highly potent member of the pyrimidinedione series in thethird quarter of 2008. In addition, ImQuest has initiated IND-enabling studieswith the pyrimidinedione IQP-0528 as a potential anti-HIV topical microbicide.
ImQuest Life Sciences, a privately held U.S. company located in Frederick,Maryland specializes in early stage drug development of novel compounds forthe treatment of infectious disease and cancer. Samjin Pharmaceutical Co., apublicly held company listed on the Korean Stock Exchange, is one of theleading pharmaceutical companies in Korea. ImQuest BioSciences, also locatedin Frederick, Maryland, is a leading provider of anti-infective and anti-cancer drug and vaccine development services to the biotechnology andpharmaceutical industry.For further information regarding this press release please contact: Robert W. Buckheit, Jr., Ph.D. Executive Vice President and Chief Scientific Officer ImQuest Life Sciences, Inc. 301-696-0274 email@example.com
SOURCE ImQuest BioSciences, Inc.
You May Also Like